Literature DB >> 21714479

Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes.

Terry H Wu1, Karin Schreiber, Ainhoa Arina, Nikolai N Khodarev, Elena V Efimova, Donald A Rowley, Ralph R Weichselbaum, Hans Schreiber.   

Abstract

Many cancers escape host immunity without losing tumor-specific rejection antigens or MHC class I expression. This study tracks the evolution of one such cancer that developed in a mouse following exposure to ultraviolet light. The primary autochthonous tumor was not highly malignant and was rejected when transplanted into naïve immunocompetent mice. Neoplastic cells isolated from the primary tumor were susceptible to the growth-inhibitory effects of IFNγ in vitro, but expressed very low levels of MHC I antigen and were resistant to tumor-specific T cells unless they were first exposed to IFNγ. Serial passage of the primary tumor cells in vivo led to a highly aggressive variant that caused fast-growing tumors in normal mice. In vitro, the variant tumor cells showed increased resistance to the growth-inhibitory effects of IFNγ but expressed high levels of immunoproteasomes and MHC I molecules and were susceptible to tumor-specific T cells even without prior exposure to IFNγ.
Copyright © 2011 by Terry H. Wu

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21714479      PMCID: PMC3127375     

Source DB:  PubMed          Journal:  Cancer Immun        ISSN: 1424-9634


  61 in total

1.  Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress.

Authors:  Ulrike Seifert; Lukasz P Bialy; Frédéric Ebstein; Dawadschargal Bech-Otschir; Antje Voigt; Friederike Schröter; Timour Prozorovski; Nicole Lange; Janos Steffen; Melanie Rieger; Ulrike Kuckelkorn; Orhan Aktas; Peter-M Kloetzel; Elke Krüger
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

Review 2.  "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.

Authors:  Federico Garrido; Teresa Cabrera; Natalia Aptsiauri
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

3.  Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma.

Authors:  Honghai Li; Xiaoyong Fu; Yao Chen; Yi Hong; Yexiong Tan; Huifang Cao; Mengchao Wu; Hongyang Wang
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

4.  MHC-linked LMP gene products specifically alter peptidase activities of the proteasome.

Authors:  J Driscoll; M G Brown; D Finley; J J Monaco
Journal:  Nature       Date:  1993-09-16       Impact factor: 49.962

5.  Sequence and expression of mouse proteasome activator PA28 and the related autoantigen Ki.

Authors:  H Jiang; J J Monaco
Journal:  Immunogenetics       Date:  1997       Impact factor: 2.846

Review 6.  Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments.

Authors:  Karin Schreiber; Donald A Rowley; Gert Riethmüller; Hans Schreiber
Journal:  Hematol Oncol Clin North Am       Date:  2006-06       Impact factor: 3.722

7.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

8.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

9.  Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.

Authors:  P L Ward; H Koeppen; T Hurteau; H Schreiber
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

10.  Tumor rejection by disturbing tumor stroma cell interactions.

Authors:  S Ibe; Z Qin; T Schüler; S Preiss; T Blankenstein
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  6 in total

Review 1.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

2.  Tumor relapse prevented by combining adoptive T cell therapy with Salmonella typhimurium.

Authors:  David C Binder; Ainhoa Arina; Frank Wen; Tony Tu; Ming Zhao; Robert M Hoffman; Derek A Wainwright; Hans Schreiber
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110

3.  The effects of IFITM1 and IFITM3 gene deletion on IFNγ stimulated protein synthesis.

Authors:  Maria Gómez-Herranz; Marta Nekulova; Jakub Faktor; Lenka Hernychova; Sachin Kote; Elizabeth H Sinclair; Rudolf Nenutil; Borivoj Vojtesek; Kathryn L Ball; Ted R Hupp
Journal:  Cell Signal       Date:  2019-04-02       Impact factor: 4.315

4.  IFN-γ Critically Enables the Intratumoural Infiltration of CXCR3+ CD8+ T Cells to Drive Squamous Cell Carcinoma Regression.

Authors:  Zhen Zeng; Margaret Veitch; Gabrielle A Kelly; Zewen K Tuong; Jazmina G Cruz; Ian H Frazer; James W Wells
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

5.  Emergent Role of IFITM1/3 towards Splicing Factor (SRSF1) and Antigen-Presenting Molecule (HLA-B) in Cervical Cancer.

Authors:  Maria Gómez-Herranz; Jakub Faktor; Marcos Yébenes Mayordomo; Magdalena Pilch; Marta Nekulova; Lenka Hernychova; Kathryn L Ball; Borivoj Vojtesek; Ted R Hupp; Sachin Kote
Journal:  Biomolecules       Date:  2022-08-08

6.  Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab.

Authors:  Sebastian P Haen; Benjamin J Schmiedel; Kathrin Rothfelder; Bastian J Schmied; Truong-Minh Dang; Nora Mirza; Robert Möhle; Lothar Kanz; Wichard Vogel; Helmut R Salih
Journal:  Oncotarget       Date:  2016-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.